Julio C. Rojas, MD, PhD

Behavioral Neurology Fellow

Julio Rojas received his medical degree from the Tecnológico de Monterrey School of Medicine in Monterrey, Nuevo León, Mexico. He completed his doctoral studies in neuroscience at the University of Texas at Austin with a dissertation on Strategies of neuroprotection in an in vivo model of retinal degeneration induced by mitochondrial dysfunction. He completed neurology residency at UT Southwestern Medical Center in Dallas. In 2014, he joined the UCSF Memory and Aging Center where he is a behavioral neurology fellow. Dr. Rojas is part of the Clinical Trials team led by Dr. Adam Boxer in which he participates in patient evaluation and monitoring. He provides care to patients with various neurodegenerative disorders and collaborates in the evaluation of patients for the Alzheimer's Disease Research Center (ADRC), frontotemporal dementia program project grant and Rapidly Progressive Dementia Program. Dr. Rojas is interested in experimental neurotherapeutics, and his research focuses on biomarker development and cognitive enhancing interventions.

Noelle Ohanesian

Asst. Clinical Research Coordinator

Originally from upstate New York, Noelle graduated from Duke University in May 2014 with a Bachelor of Science degree in neuroscience and a history minor. While attending school, she worked as a research assistant in Duke's Center for Cognitive Neuroscience, running a study examining the effects of acute stress on memory retention. She also spent a summer working for the Behavioral Lab in the Duke University Fuqua School of Business studying social mimicry in anorexic subjects. Outside of her academic interests, she worked as the Program Director of Duke’s backpacking organization, Project WILD, in which she directed one- and two-week backpacking programs for the freshmen class. Noelle joined the UCSF Memory and Aging Center in June 2014 as a member of the clinical trials team under Dr. Adam Boxer. She is a research coordinator for the asymptomatic Alzheimer’s disease trial.

Caitlin Glennon


Caitlin joined the Memory and Aging Center in March 2014. She is currently an analyst working on Dr. Boxer’s clinical trials and research studies. She previously worked in the Department of Neurology at UCSF with the Stroke Sciences Group on both industry and NIH-funded clinical trials.

Asymptomatic Alzheimer’s Disease Anti-Amyloid Trial

The purpose of this study is to test whether an investigational drug called solanezumab can slow the progression of memory problems associated with brain amyloid (the protein that forms plaques in the brains of people with Alzheimer’s disease) as compared with placebo in subjects with preclinical AD.


  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Eli Lilly & Company and National Institute on Aging (NIA)
  • Recruiting?: Yes
  • Official study title: Anti-Amyloid Treatment in Asymptomatic Alzheimer’s Disease (A4 Study)
  • identifier: NCT02008357


A selection of the abstracts and manuscripts published using EXAMINER data.

The publications listed on this page are a selection of the articles published that used the EXAMINER battery. If you wish to look for more, you can search PubMED, which is maintained by the National Library of Medicine, or Google Scholar.


  1. Kramer, J.H. (2014). Special Series Introduction: NIH EXAMINER and the Assessment of Executive Functioning. Journal of the International Psychological Society, 20(1), 8-10. doi: 10.1017/S1355617713001185

Panos Theofilas, PhD

Postdoctoral Scholar

Panos Theofilas joined the Grinberg lab at the UCSF Memory and Aging Center in 2012. His research focuses on the neuropathological changes and susceptibility of subcortical brain regions in the earliest stages of Alzheimer's disease. Dr. Theofilas’ methodology includes analyses of human brain circuitries as a whole by combining unbiased stereology, immunohistochemistry/biochemical assays, and 3D computer graphics for histological brain volume reconstructions. His academic background includes a BSc degree in zoology and an MSc degree in neuroscience from the University of Edinburgh, UK. He completed his PhD degree at Bonn University in Germany on programmed cell death signaling pathways in animal models of temporal lobe epilepsy.

Alzheimer’s Disease Trial of Levetiracetam

The purpose of this study is to evaluate whether the anti-epileptic drug levetiracetam reduces subclinical (clinically silent) epileptiform activity and improves cognition in people with Alzheimer’s disease. Epileptiform activity is a term used to describe the abnormal firing of neurons in ways similar to epilepsy or seizure disorder.


  • Study director: Keith Vossel, MD, MSc
  • Sponsor: Alzheimer’s Association, Inc.; NIH National Institute on Aging; S.D. Bechtel, Jr. Foundation
  • Recruiting?: Yes
  • Official study title: A Phase 2A Levetiracetam Trial for Alzheimer’s Disease—Associated Network Hyperexcitability

Frequently Asked Questions (FAQ)

Read through our list of commonly asked questions about using the NIH EXAMINER Test Battery.


Q: Are there norms for each individual subtest or just the composite scores? We are hoping to get age- or age-and-education-based norms.

Alzheimer’s Disease Trial with TPI-287

Tau is a microtubule-associated protein, and abnormal tau function has been proposed to play a role in the development and progression of Alzheimer’s disease (AD). TPI-287 is an stabilizer of microtubule dynamics, and the stabilization of microtubules is hypothesized to compensate for the loss of tau function in AD. The purpose of this study is to determine the dose of TPI-287 that is safe and tolerable in people with mild to moderate AD, as well as to measure the properties and preliminary efficacy of TPI-287.


  • Study director: Adam Boxer, MD, PhD
  • Sponsor: UCSF (Funder: Alzheimer’s Association)
  • Recruiting?: Yes
  • Official study title: A Phase I, Randomized, Double-Blind, Placebo-Controlled, Sequential Cohort, Dose-Ranging Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TPI-287 in Patients with Mild to Moderate Alzheimer’s Disease

Alzheimer’s Disease Trial of Solanezumab

The production and deposition of amyloid plaques in the brain is thought to contribute to the development and progression of Alzheimer’s disease (AD). Solanezumab is hypothesized to reduce accumulation of amyloid plaques and thus slow the progression of AD. The primary purpose of the study is to determine if solanezumab will slow cognitive and functional decline in participants with mild AD.


  • Study director: Adam Boxer, MD, PhD
  • Sponsor: Eli Lilly & Company
  • Recruiting?: Not recruiting
  • Official study title: Effect of Passive Immunization on the Progression of Mild Alzheimer’s Disease: Solanezumab (LY2062430) Versus Placebo
  • identifier: NCT01900665
  • Conditions studied: Mild Alzheimer's disease
Syndicate content